MHRA approves Valneva’s chikungunya vaccine Ixchiq for use in adults
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent disease caused by the chikungunya virus (CHIKV) in individuals aged 18 years and older.
Valneva jumps 19% after chikungunya vaccine wins UK approval
Shares of Valneva (VALN), a specialty vaccine company closed up over $1.00 per share or almost 19% to close the regular session at $6.67 per
Valneva receives authorisation for world’s first Chikungunya vaccine
Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is indicated for active immunisation for the prevention of disease caused by Chikungunya virus (CHIKV) in individuals 18 years of age and older.
Valneva rises after U.K. approval of chikungunya vaccine
Shares of Valneva (NASDAQ:VALN) traded higher on Wednesday after the French biotech announced that the U.K.’s Medicines and Healthcare Products Regulatory Agency granted marketing authorization for its chikungunya vaccine.
Valneva’s chikungunya vaccine wins UK approval
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults. France-based Valneva has also submitted label extension applications in the US,
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci
Valneva stock holds $18 target on UK vaccine nod
H.C. Wainwright reaffirmed its Buy rating and $18.00 price target for Valneva (EPA:VLS) SE (NASDAQ:VALN) shares, following the recent approval of the company's Ixchiq vaccine in the United Kingdom ...
Kepler Capital Sticks to Its Buy Rating for Valneva (0OB3)
In a report released on February 5, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a ...
FiercePharma4d
Valneva snares $33M contract to supply US with Japanese encephalitis vaccine
While much of Valneva's focus these days is centered on its landmark vaccine for chikungunya virus, the French immunization specialist's catalog of older shots continues to serve up fresh governmen | ...
Shareholding declaration Valneva SE - January 2025
VALNEVA Declaration of shares and voting rights January 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue ...
pharmaphorum7d
Valneva gets $41m grant to roll out chikungunya vaccine
Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...
What is HC Wainwright’s Estimate for Valneva Q1 Earnings?
Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Valneva in a research note ...